Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pogue

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Nature Cancer|April 3, 2023
Publisher Correction: Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutatedTanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Breast Cancer Research : BCR|May 24, 2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Breast Cancer Research : BCR|April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Nature Cancer|April 3, 2023
Publisher Correction: Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutatedTanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Breast Cancer Research : BCR|May 24, 2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Breast Cancer Research : BCR|April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
Pageof 7